In focus · trending topic

axsome

64 stories · following the connections

Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017

By Nasdaq OMXSep 7, 2017, 11:00 AM UTC

Axsome Therapeutics Reports Second Quarter 2017 Financial Results

By Nasdaq OMXAug 9, 2017, 11:00 AM UTC

Axsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial

By Nasdaq OMXJul 25, 2017, 11:01 AM UTC

Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation

By Nasdaq OMXJul 17, 2017, 11:00 AM UTC

Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer

By Nasdaq OMXJul 6, 2017, 11:00 AM UTC

Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors

By Nasdaq OMXJun 19, 2017, 11:00 AM UTC

Axsome Therapeutics Reports First Quarter 2017 Financial Results

By Nasdaq OMXMay 9, 2017, 11:02 AM UTC

Axsome Therapeutics Reports First Quarter 2017 Financial Results

By Nasdaq OMXMay 9, 2017, 11:02 AM UTC